A Novel Dopaminergic Modulator (NDM-101) as an Adjunct to Levodopa: Enhancing Motor Control Without Worsening Dyskinesia in Parkinson’s Disease
Objective: To evaluate the efficacy and safety of NDM-101 as an adjunct to levodopa in reducing OFF-time, improving motor function, and maintaining quality of life…Plasma neurofilament light chain in early Parkinson’ s disease predicts motor complications: A Prospective Cohort Study
Objective: The current study aimed to identify risk plasma biomarkers in early-stage PD for future motor complications through a longitudinal Chinese PD cohort, which ultimately…Optimizing deep brain stimulation programming settings for patients with stimulation-induced dyskinesias in Parkinson’s disease
Objective: To assess the impact of Deep Brain Stimulation (DBS) parameters on stimulation-induced dyskinesias (SID) in patients with Parkison’s Disease (PD). Background: SID resemble levodopa-induced…Association Between Pesticide Exposure and Clinical Outcomes in Parkinson’s Disease: A Propensity-Matched Cohort Study
Objective: To evaluate the clinical outcomes associated with pesticide exposure in Parkinson’s disease (PD) participants in the Canadian Open Parkinson Network (COPN)(1). Background: Pesticide exposure…Foscarbidopa/Foslevodopa Therapy Improves Continuous Duration of Good ON Time and Correlated With Quality of Life in People With Parkinson’s Disease
Objective: To assess the impact of foscarbidopa/foslevodopa (CDp/LDp) continuous subcutaneous infusion (CSCI) on longest consecutive duration of Good and Best ON time and association of…Quality of Life Impact on Adults with Parkinson’s Disease Experiencing Morning Akinesia: Real-World Observational Findings
Objective: To compare the quality of life (QoL) in Parkinson’s Disease (PD) patients with and without morning akinesia (MA) in those using oral medications only…Impact of ND0612 on Levodopa-Induced Dyskinesia in Parkinson’s Disease: Post hoc Analyses From a Randomized, Active-Controlled Study
Objective: To evaluate dyskinesia-related outcomes between optimized subcutaneously administered levodopa/carbidopa (ND0612) + immediate-release levodopa/carbidopa (IR-LD/CD) vs optimized oral IR-LD/CD in patients with Parkinson’s disease (PD).…Safety and tolerability of overnight switching from Eetacapone to Opicapone in fluctuating Parkinson’s disease: An open-label preliminary trial in Koreans
Objective: Objectives: 1. Efficacy - Opicapone 50mg qd. to determine effectiveness of optimal dose for switching. 2. Tolerability and safety - compare symptoms and adverse…Longitudinal Remote Monitoring with Wearable Technology in Parkinson Disease: Initiation of A Dyskinesia Insight Network Observational Study
Objective: Evaluate the utility of wearable digital health technology for identifying and characterizing levodopa-induced dyskinesia in real-world settings. Background: Patients with Parkinson disease (PwP) frequently…The Unique Clinical Profile of Dystonia in Parkinson Disease
Objective: Characterize clinical features of dystonia and levodopa-related dyskinesias in Parkinson disease (PD). Background: Dystonia affects 30-60% of individuals with PD. [1] Despite recognition as…
- 1
- 2
- 3
- …
- 44
- Next Page »